Oncology

NCT04153344 – Function of the Pigment Epithelium in Patients With Type 1 Neurofibromatosis

NCT04920617 – DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blasts derived from patients with CLL

Mice – CLL grafted mice (blasts)

Tumor grafting in mice (CLL)

Patient cohort

Blasts derived from patients with CML

Mice – CML grafted mice (blasts)

Tumor grafting in mice (CML)

Patient cohort

Blasts derived from ALL patients

Cell lines from patients with ALL

Mice – ALL grafted mice (blasts)

Tumor grafting in mice

Patient cohort

NCT03750994 – Economic Evaluation of Innovative Molecular Analyses in Onco-haematology (PRME-K 2016)

Blood from patients with mastocytosis

Methods and pharmaceutical compositions for the treatment of mast cell diseases

Methods and pharmaceutical compositions for the treatment of systemic mastocytosis

>500 Pediatric and adult (Mastocytosis)

NCT04910685 – (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT06186856 – Epidemiological Data on Mast Cell Pathologies in France

NCT04703192 – Valemetostat Tosylate (DS-3201b) an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

NCT04984837 – Study of Lacutamab in Peripheral T-cell Lymphoma

NCT05444712 – Transplantation After Complete Response In Patients With T-cell Lymphoma

Mice – MDS grafted mice (bone marrow – blasts)

Tumor grafting in mice (MDS)

Xpo1 antagonist kpt-251 for the treatment of myelodysplastic syndrome

Patient cohort

NCT03750994 – Economic Evaluation of Innovative Molecular Analyses in Onco-haematology (PRME-K 2016)

NCT05181735 – Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Blasts derived from patients with mantle cell lymphoma

Lymphoma cell lines

Mantle cell lymphoma grafted mice (blasts)

Tumor grafting in mice (Mantle cell lymphoma)

Patient cohort

NCT05471843 – Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

NCT04802590 – Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Bone marrow from patients with mast cell leukemia

Mice – Mast cell leukemia grafted mice (bone marrow)

Protocol with Mast cell leukemia grafted mice (bone marrow)

Tumor grafting in mice (Mast cell leukemia)

Patient cohort

Mice – Human PDX in NOD SCID mice

Blasts derived from patients with AML

Cell lines from patients with AML

Human AML cell lines (AML)

Mice – AML grafted mice (blasts)

Tumor grafting in mice (AML)

Patient cohort associated with GOELAMS

NCT03750994 – Economic Evaluation of Innovative Molecular Analyses in Onco-haematology (PRME-K 2016)

NCT05020665 – Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

NCT05193448 – A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE

NCT05070208 – Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor

NCT04777916 – Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

NCT05260528 – CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics